- Home
- STKS vs TVGN Comparison
STKS vs TVGN Comparison
Compare STKS & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STKS | TVGN |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 63.9M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | STKS | TVGN |
|---|---|---|
| Price | $1.85 | $5.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $4.70 | N/A |
| AVG Volume (30 Days) | 20.1K | ★ 20.7K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $805,722,000.00 | N/A |
| Revenue This Year | $7.47 | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.65 | $0.14 |
| 52 Week High | $4.67 | $12.03 |
Technical Indicators
Market Signals| Indicator | STKS | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 32.33 |
| Support Level | $1.70 | $0.34 |
| Resistance Level | $2.06 | $5.64 |
| Average True Range (ATR) | 0.12 | 0.99 |
| MACD | -0.00 | -0.48 |
| Stochastic Oscillator | 20.95 | 3.98 |
Price Performance
Historical ComparisonAbout STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.